Intrathecal insulin-like growth factor 1 but not insulin enhances myelin repair in young and aged rats

•Insulin-like growth factor 1 (IGF-1) enhanced remyelination in young and aged rats.•Insulin, functionally related to IGF-1, did not enhance remyelination.•Aged rats show less pronounced myelin repair compared to young rats.•Aged rats are model for chronic demyelination faced in chronic multiple scl...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience letters 2017-05, Vol.648, p.41-46
Main Authors: Hlavica, Martin, Delparente, Aro, Good, Andrin, Good, Nicolas, Plattner, Patricia S., Seyedsadr, Maryam S., Schwab, Martin E., Figlewicz, Dianne P., Ineichen, Benjamin V.
Format: Article
Language:English
Subjects:
Animals
Blood Glucose
Cell Count
Demyelinating Diseases - chemically induced
Demyelinating Diseases - prevention & control
Female
IGF-1
Injections, Spinal
Insulin
Insulin - administration & dosage
Insulin-Like Growth Factor I - administration & dosage
Intrathecal
Lysolecithin
Lysophosphatidylcholines
Macrophages - drug effects
Macrophages - metabolism
Multiple sclerosis
Myelin Sheath - drug effects
Rat
Rats
Rats, Long-Evans
Remyelination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Insulin-like growth factor 1 (IGF-1) enhanced remyelination in young and aged rats.•Insulin, functionally related to IGF-1, did not enhance remyelination.•Aged rats show less pronounced myelin repair compared to young rats.•Aged rats are model for chronic demyelination faced in chronic multiple sclerosis. One main pathological hallmark of multiple sclerosis (MS) is demyelination. Novel therapies which enhance myelin repair are urgently needed. Insulin and insulin-like growth factor 1 (IGF-1) have strong functional relationships. Here, we addressed the potential capacity of IGF-1 and insulin to enhance remyelination in an animal demyelination model in vivo. We found that chronic intrathecal infusion of IGF-1 enhanced remyelination after lysolecithin-induced demyelination in the spinal cord of young and aged rats. Aged rats showed a weaker innate remyelination capacity and are therefore a good model for progressive MS which is defined by chronic demyelination. In contrast to IGF-1, Insulin had no effect on remyelination in either age group. Our findings highlight the potential use of IGF-1 as remyelinating therapy for MS, particularly the progressive stage in which chronic demyelination is the hallmark.
ISSN:0304-3940
1872-7972
DOI:10.1016/j.neulet.2017.03.047